About: How did we rapidly implement a convalescent plasma program?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: How did we rapidly implement a convalescent plasma program? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	How did we rapidly implement a convalescent plasma program?
Creator	Hillyer, Christopher Strauss, Donna Alberigo, Jill Bloch, Evan Budhai, Alexandra Hall, Lucette Jett, Betsy Paradiso, Sarai Sachais, Bruce Shaz, Beth Tobian, Aaron Wu, Annie
Source	Medline; PMC
abstract	Since the beginning of the COVID‐19 pandemic, the use of convalescent plasma as a possible treatment has been explored. Here we describe our experience as the first US organization creating a COVID‐19 convalescent plasma program to support compassionate use through the single patient emergency IND, the National Expanded Access Program and multiple randomized control trials. Within weeks, we were able to distribute over 8000 products, scale up collections to over 4,000 units per week, meet hospital demand, as well as support randomized controlled trials to evaluate the efficacy of convalescent plasma treatment. This was through strategic planning, re‐deployment of staff, and active engagement of hospital, community, and public health partners. Our partners helped with donor recruitment, testing, patient advocacy, and patient availability. The program will continue to evolve as we learn more about optimizing the product. Remaining issues to be resolved are antibody titers, dose, and at what stage of disease to transfuse.
has issue date	2020-05-25(xsd:dateTime)
bibo:doi	10.1111/trf.15910
bibo:pmid	32449169
has license	no-cc
sha1sum (hex)	afe921ede5dd26d51cc5715534e52557fe227b77
schema:url	https://doi.org/10.1111/trf.15910
resource representing a document's title	How did we rapidly implement a convalescent plasma program?
has PubMed Central identifier	PMC7283779
has PubMed identifier	32449169
schema:publication	Transfusion
resource representing a document's body	covid:afe921ede5dd26d51cc5715534e52557fe227b77#body_text
is schema:about of	named entity 'active' named entity 'single' named entity 'plasma' named entity 'titers' named entity 'donor' named entity 'convalescent' named entity 'rapidly' named entity 'ENGAGEMENT' named entity 'STRATEGIC PLANNING' named entity 'DESCRIBE' named entity 'TO SUPPORT' named entity 'SINGLE' named entity 'DEMAND' named entity 'CREATING' named entity 'CONTINUE' named entity 'PRODUCTS' named entity 'EXPERIENCE' named entity 'COMPASSIONATE USE' named entity 'TREATMENT' named entity 'PARTNERS' named entity 'RANDOMIZED' named entity 'AVAILABILITY' named entity 'SCALE' named entity 'PRODUCT' named entity 'ORGANIZATION' named entity 'COVID-19 PANDEMIC' named entity 'Our' named entity 'antibody test' named entity 'electronic medical records' named entity 'IND' named entity 'critically ill' named entity 'positive test' named entity 'virus' named entity 'convalescent' named entity 'convalescent' named entity 'evolve' named entity '28 days' named entity 'asymptomatic' named entity 'source plasma' named entity 'critically ill patients' named entity 'BECS' named entity 'Institutional Review Board' named entity 'FDA' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'infectious disease' named entity 'serological test' named entity 'pediatric patients' named entity 'neutralizing antibody' named entity 'Convalescent Plasma' named entity 'FDA' named entity 'blood product' named entity 'Phase II' named entity 'Convalescent Plasma' named entity 'pandemic' named entity 'units' named entity 'controlled' named entity 'public health' named entity 'transfuse' named entity 'COVID-19' named entity 'blood center' named entity 'COVID-19' named entity 'BARDA' named entity 'SARS' named entity 'blood donation' named entity 'EAP' named entity 'HIPPA' named entity '1:160' named entity 'red blood cell'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software